Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2017

Rafael Pharma launches Phase I pancreatic cancer trial

US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination with chemotherapeutics, gemcitabine, and nab-paclitaxel to treat patients with pancreatic cancer.

US-based Rafael Pharmaceuticals has launched a Phase I clinical trial of its drug candidate CPI-613 to be assessed in combination with chemotherapeutics, gemcitabine, and nab-paclitaxel to treat patients with pancreatic cancer.

CPI-613 is being developed as an altered energy metabolism directed (AEMD) drug to target the mitochondrial metabolism of cancer cells for disrupting their altered energy-production pathways.

To be performed in partnership with Atlantic Health System, the Phase I trial will evaluate the combination therapy in subjects with locally advanced or metastatic pancreatic cancer.

The trial’s primary objective is to determine the maximum tolerated dose of CPI-613 when administered in conjunction with the chemotherapeutics.

Rafael Pharmaceuticals CEO Sanjeev Luther said: “Patients with a low-tolerance for toxicity may not be eligible for the Folfirinox combo.

“Patients with a low-tolerance for toxicity may not be eligible for the Folfirinox combo.”

“We believe that the gemcitabine/nab-paclitaxel regimen has the potential to be a potent treatment with less toxicity.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

The secondary objectives of the Phase I trial are safety and clinical activity of the combination, progression-free survival (PFS) and overall survival (OS).

Trial principal investigator Dr Angela Alistar said: “Due to the low toxicity profile of CPI-613 as a single agent, I anticipate good tolerance in combination with the gemcitabine/nab-paclitaxel regimen.”

Previous trial results are reported to have demonstrated the favourable safety and tolerability profile of CPI-613, which is under assessment in various Phase I, I/II and II trials.

CPI-613 obtained orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of acute myeloid leukaemia (AML), pancreatic cancer and myelodysplastic syndromes (MDS).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU